ArticleInvestigative ophthalmology & visual science2026
Sparse Cell Labeling Reveals Morphologic Diversity Among Mouse Scleral Fibroblasts.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Purpose: The purpose of this study was to investigate mouse scleral cell morphology in healthy and ocular hypertensive eyes. Methods: B6.Cg-Ndor1Tg (UBC-cre/ERT2) 1Ejb/1J (UBC-Cre-ERT2) (Strain # 007001; Jackson Labs, Bar Harbor, ME, USA) were crossed with Gt(ROSA)26 Sor tm1(CAG-Brainbow2.1)Cle /J (R26R-Confetti) (Strain # 017492, Jackson Labs) to obtain hemizygous offsprings (UBC-Confetti). This enables tamoxifen-induced recombination of the Brainbow 2.1 cassette, inducing random expression of fluorescent proteins in all cells. Two weeks after tamoxifen treatment (intraperitoneal injection, n = 7 mice), anterior chamber bead injection raised the intraocular pressure (IOP). Eyes were enucleated 3 days after bead injection. YFP and GFP-labeled peripapillary scleral (PPS) and peripheral scleral cells were imaged, cell volume was measured, and individual cell morphology was highlighted using Imaris (version 9.3; 89 control and 136 glaucomatous cells). Results: Imaging of YFP/GFP-labeled cells allowed visualization of individual scleral cells. Differences in the intensity of the Confetti YFP/GFP signal compared to nuclear and fibrillar actin (FA) labels enabled visualization of FA and nuclear structure within YFP/GFP-labeled cells. Under baseline conditions, cells were morphologically diverse, displayed migratory structures, and extensions into the surrounding extracellular matrix (ECM). Mean PPS cell volume (692 µm3, interquartile range [IQR] = 419.8-1304 µm3, n = 62 cells) was greater than peripheral cell volume (336 µm3, IQR = 217-488 µm3, n = 27 cells, P < 0.0001). Cells in glaucomatous eyes exhibited similar morphologic diversity and had reduced PPS cell volume compared with controls (277 µm3, IQR = 154-532, n = 83 cells, P < 0.0001). Conclusions: Sparse cell labeling allowed visualization of individual cell morphology in the scleral environment. Cells demonstrated diverse morphologies, and PPS cells responded to IOP elevation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.